A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenecity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory

Grants and Contracts Details

StatusFinished
Effective start/end date1/1/0812/31/12

Funding

  • Wyeth Pharmaceuticals Inc: $159,452.00